News & Updates
Filter by Specialty:
Rapid test for COVID-19 not so perfect
Panbio, a rapid antigen test for SARS-CoV-2, has good specificity but limited sensitivity, as shown in a study. As such, all negative tests have to be confirmed with RT-PCR, especially in the presence of related symptoms, in settings with high community infection rate, and in cases of direct contact with confirmed COVID-19 patients.
Rapid test for COVID-19 not so perfect
01 Nov 2021Air pollution compromises exercise responses more in healthy people than ex-smokers
Exposure to traffic-related air pollution takes a toll on exercise responses among healthy people but not former smokers with or without chronic obstructive pulmonary disorder (COPD), a study has found.
Air pollution compromises exercise responses more in healthy people than ex-smokers
31 Oct 2021Adjuvant atezolizumab improves DFS in early-stage NSCLC
In patients with completely resected stage II–IIIA non-small-cell lung cancer (NSCLC) who had previously received adjuvant cisplatin chemotherapy, adjuvant atezolizumab extended disease-free survival (DFS), particularly in those with PD-L1 expression ≥1 percent on tumour cells, interim results of the phase III IMpower010 trial showed.
Adjuvant atezolizumab improves DFS in early-stage NSCLC
27 Oct 2021Helmet-CPAP safely improves oxygenation in pregnant women with COVID-19 respiratory failure
Administrating continuous positive airway pressure (CPAP) through a helmet (h-CPAP) device safely improves oxygenation in women with moderate-to-severe acute respiratory failure (ARF) due to the coronavirus disease 2019 (COVID-19), a recent study has found.
Helmet-CPAP safely improves oxygenation in pregnant women with COVID-19 respiratory failure
27 Oct 2021Durvalumab + tremelimumab + chemo: A new first-line SoC for mNSCLC?
The combination of durvalumab, tremelimumab, and chemotherapy in the first-line setting improved progression-free survival (PFS) and overall survival (OS) in patients with metastatic non-small-cell lung cancer (mNSCLC), according to results of the phase III POSEIDON trial.